J.M. Hartwell’s Coherus Oncology CHRS Stock Holding History

J.M. Hartwell’s Portfolio CHRS Stock Details CHRS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q3	–	Sell	-10,000	Closed	-$140K	–	86
2018 Q2	$140K	Buy	+10,000	New	+$143K	0.03%	80

Other funds holding CHRS

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Temasek Holdings Singapore $30.5B AUM 13.98% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

KKRC

Kohlberg Kravis Roberts & Co New York $5.35B AUM 63.01% 1-Year Est. Return

Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Hound Partners New York $799M AUM 9.54% 1-Year Est. Return

J.M. Hartwell's CHRS Position: Q3 2018 in Review

J.M. Hartwell sold out of Coherus Oncology (CHRS) in Q3 2018, closing a stake of 10,000 shares — an estimated $140K sold.

J.M. Hartwell first reported a position in CHRS in Q2 2018 and held it in 1 quarter. The position peaked at $140K in Q2 2018. 109 funds tracked by Wall St. Rank hold CHRS as of Q3 2018.

J.M. Hartwell reported no remaining Coherus Oncology position as of Q3 2018 after selling out during the quarter.
J.M. Hartwell sold 10,000 Coherus Oncology shares in Q3 2018, an estimated $140K.
J.M. Hartwell first reported a position in Coherus Oncology in Q2 2018 and held it in 1 quarter.
J.M. Hartwell's Coherus Oncology position peaked at $140K in Q2 2018.
109 funds tracked by Wall St. Rank held Coherus Oncology as of Q3 2018.

Based on J.M. Hartwell's 13F filing for Q3 2018, filed 29 Oct 2018.